Gutenberg Research
  • Home
  • Models
    • Modeling Approach
  • Education
    • Cooperative Education Program
    • Book >
      • Book Registration - Third Edition >
        • Templates - Third Edition
      • Book Registration - Second Edition >
        • Templates - Second Edition
    • Intern Program >
      • New Intern Sign-up
      • Intern Training (Winter 2020 Round)
      • Intern Program Exam
      • Intern Bio Form
      • Intern Model Submission
  • About
    • Contact
    • Email Distribution Sign-up
    • Terms of Use
    • Privacy Policy
Picture

Frank DePinto's Contributor Page

Frank, a Level I candidate in the CFA program, is a senior at the University of Delaware, planning to work for J.P. Morgan after graduation. Frank is an options specialist and a head of the Healthcare Sector for the Blue Hen Investment Club, a student-managed equity fund that oversees ~1.7 million AUM of the university's endowment.​
Contributor Number: 123

Frank's Models

Jazz Pharma (NASDAQ:JAZZ)
​Last Update:
 November 20, 2016
View on Jazz: Bearish
Summary of Model Estimates: Updated Q32016 financials and lowered assumptions for 2017 revenue and EPS assumptions. According to commentary in the 10-K, Jazz is facing increasing threats from generic competition. The firm is also too reliant for my liking on sales of Xyrem, the primary drug facing generic competition. I also don't believe that Jazz is developing drugs in areas that are poised for tremendous patient growth or areas of unmet medical need. It seems like a majority of their clinical trial outlook is related to new indications for existing drugs in their portfolio. All in all, I don't necessarily have the most upbeat outlook for Jazz Pharmaceuticals for FY2017.
Frank DePinto JAZZ.xlsx
File Size: 88 kb
File Type: xlsx
Download File

Gutenberg Research is a media and entertainment company. The information presented on our website and within Gutenberg Research models, files, or other content does not represent investment advice. Data and information presented on this website, or on third party websites posted by us, within our models, files, and other content is for demonstration only, and is presented “as is”. Neither Gutenberg Research nor any Gutenberg Research agents or associates are liable for any errors, delays, incompleteness of data presented, or for actions taken based on reliance on any information contained on this website or within Gutenberg Research models or other content. Investors should consult a professional investment adviser prior to making investment decisions. By accessing this site and/or receiving our models or other content you are deemed to have read and agreed to our Terms of Use posted on this website. This website uses Cookies, refer to our Privacy Policy for details. The Gutenberg Research logo is among the registered and unregistered trademarks of Gutenberg Research LLC. © Gutenberg Research LLC 2021. All Rights Reserved.